DexCom (DXCM) Expected to Release Quarterly Earnings on Thursday

DexCom (NASDAQ:DXCM) is expected to post its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of $0.61 per share and revenue of $1.2903 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the business earned $0.32 earnings per share. DexCom’s revenue for the quarter was up 15.0% compared to the same quarter last year. On average, analysts expect DexCom to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $73.37 on Tuesday. DexCom has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $28.31 billion, a price-to-earnings ratio of 31.35, a PEG ratio of 1.18 and a beta of 1.45. The firm has a 50-day moving average of $72.63 and a two-hundred day moving average of $68.97.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on DXCM shares. Bank of America lowered their price objective on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Citigroup restated a “buy” rating and issued a $84.00 price target (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Deutsche Bank Aktiengesellschaft initiated coverage on DexCom in a research report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price objective for the company. Robert W. Baird set a $80.00 target price on DexCom in a report on Friday, May 1st. Finally, Benchmark reiterated a “buy” rating on shares of DexCom in a report on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $85.36.

Insider Buying and Selling at DexCom

In other DexCom news, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director directly owned 52,852 shares of the company’s stock, valued at $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares in the company, valued at approximately $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 71,750 shares of company stock worth $5,163,241 over the last quarter. Insiders own 0.28% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. DV Equities LLC acquired a new stake in DexCom in the 4th quarter worth approximately $36,000. Aster Capital Management DIFC Ltd bought a new position in shares of DexCom in the fourth quarter valued at approximately $63,000. Quarry LP acquired a new stake in shares of DexCom in the third quarter worth $72,000. Summit Securities Group LLC lifted its stake in shares of DexCom by 817.2% in the fourth quarter. Summit Securities Group LLC now owns 1,174 shares of the medical device company’s stock worth $78,000 after buying an additional 1,046 shares during the last quarter. Finally, Palisade Asset Management LLC bought a new stake in shares of DexCom during the 3rd quarter worth $81,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.